基因编辑权威指南。
菜单
首页 学习 新闻 向 Atlas 提问
探索 技术 疾病 治疗方法 临床试验 企业 科学家 基因 研究 机构
医学之外 农业 伦理 投资 世界地图
学习与工具 从这里开始 术语表 A–Z 对比技术 时间线 列表与排名 AI 智能体 ★ 已保存 API
关于 关于我们 方法论 数据来源 编辑方针 联系我们 免责声明

🧭 引导视图
遗传学新手?浏览时我们会用简单易懂的语言为您解释每个术语,就在同一页面内,帮助随时可用。

⚡ 专家观点
你已经了解生物学基础,只需内容本身——简洁明了,无额外解释。这是默认视图。

界面语言
浅色模式

临床试验 · Inherited blindness

BRILLIANCE — the first in vivo CRISPR administration to a human organ

官方名称: Single Ascending Dose Study of EDIT-101 in Participants With Leber Congenital Amaurosis Type 10

Completed Phase I/II NCT03872479
Clinical research Being tested in people in registered clinical trials. Being in trials is not evidence that a treatment works or is safe.

本试验正在测试什么

The first time CRISPR was injected directly into a human organ — under the retina, to remove a faulty piece of a gene causing severe inherited blindness. Some participants saw meaningfully better. The programme was later discontinued because too few people in the world have that exact mutation.

An open-label, single ascending dose Phase 1/2 study of EDIT-101, delivered by subretinal AAV5 injection, in participants with CEP290-associated Leber congenital amaurosis type 10. Published results reported clinically meaningful improvement in visual function in a subset of participants with an acceptable safety profile. Editas subsequently discontinued development for population-size reasons.

Sources

试验结果意味着什么,又不意味着什么 早期试验结果来自少量参与者和较短的随访周期,随着人数增加和时间延长,结论可能发生变化。正在招募、进行中甚至已完成的试验,并不代表某种疗法已被证实有效。入组标准十分严格,是否符合条件由试验机构决定,而非由网站判断。

Connected in the Atlas

Every entry on this site is linked to the others it relates to. These connections are part of the record, not a search result.

Genes

CEP290

Companies

Editas Medicine